CPC A61L 27/18 (2013.01) [A61K 31/4535 (2013.01); A61L 27/54 (2013.01); A61L 27/58 (2013.01); A61L 2400/06 (2013.01); A61L 2430/02 (2013.01)] | 10 Claims |
1. An In-situ forming implant formulation comprising: poly (lactide-co-glycolide) (PLGA) copolymer in concentration range from 5% to 20% w/v, a selective estrogen receptor modulator, 1-monolinolein in concentration range from 5% to 10% w/v, and an organic solvent.
|